News

In The News ADVI’s Lindsay Bealor Greenleaf told BioWorld that whether the launch interchangeable insulin biosimilars will result in lower costs for patients will be decided by PBMs.
In The News ADVI’s Lindsay Bealor Greenleaf spoke to BioWorld about the latest congressional scrutiny around prescription drug list price increases and the overlooked role played by pharmacy benefit managers.
In The News ADVI’s Lindsay Bealor Greenleaf spoke to AISHealth about CMS’ recent proposal to rein in pharmacy price concessions imposed by pharmacy benefit managers
In The News ADVI’s Lindsay Bealor Greenleaf spoke to AIS Health about a new report on PBMs & their ability to manufacture profits at the expense of patients.
In The News The House passed the Build Back Better reconciliation bill on Friday, which includes authorization for the government to negotiate lower drug prices. ADVI Health’s Lindsay Bealor Greenleaf shared insights on the measure with Pharmacy Times
In The News ADVI’s Lindsay Bealor Greenleaf shared her insights with AISHealth on a majorly overlooked aspect of the Build Back Better Act
In The News ADVI’s Lindsay Bealor Greenleaf talked to Pharmacy Times about the role of the federal government in drug pricing & how the Build Back Better Act would impact it moving forward
In The News Caitlin Sheetz, Director and Head of Analytics at ADVI, spoke with Kaiser Health News’ Julie Appleby about the Trump administration’s now-in-effect hospital price transparency rule, offering consumers advice on how to find hospitals’ shoppable services.
In The News ADVI’s Head of Analytics, Caitlin Sheetz, spoke with Robert King from FierceHealthcare about CMS’ approach to hospitals price transparency: